The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Stohl, W.
Right arrow Articles by Kiener, P. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stohl, W.
Right arrow Articles by Kiener, P. A.
The Journal of Immunology, 1998, 161: 3292-3298.
Copyright © 1998 by The American Association of Immunologists

Superantigen-Driven, CD8+ T Cell-Mediated Down-Regulation: CD95 (Fas)-Dependent Down-Regulation of Human Ig Responses Despite CD95-Independent Killing of Activated B Cells1

William Stohl2,*, David H. Lynch{dagger}, Gary C. Starling{ddagger} and Peter A. Kiener{ddagger}

* Department of Medicine, Division of Rheumatology and Immunology, University of Southern California, Los Angeles, CA 90033; {dagger} Department of Immunobiology, Immunex Corporation, Seattle, WA 98101; and {ddagger} Department of Immunology and Inflammation, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, NJ 08543

Staphylococcal superantigens, including staphylococcal enterotoxin B (SEB), promote vigorous T cell-dependent Ig responses at low dose (0.01 ng/ml). In contrast, more mitogenic high dose SEB (100 ng/ml) profoundly inhibits the Ig responses. To assess the contribution of CD8+ T cells to this inhibition, high dose SEB-dependent killing of activated B cells and down-regulation of Ig responses were determined. Rapid killing (4 h) of activated B cells was effected by high dose SEB-activated CD8+ T cells (CD8*), but not by high-dose SEB-activated CD4+ T cells (CD4*), and required the presence of high dose SEB during the cytotoxicity assay. This killing was abrogated by chelation of extracellular calcium or by treatment with concanamycin A but was only modestly affected by treatment with brefeldin A, suggesting a perforin-based pathway of killing. Despite their widely disparate abilities to rapidly kill activated B cells, CD8* and CD4* demonstrated similar quantitative abilities to effect high dose SEB-dependent down-regulation of Ig responses. Antagonist anti-CD95 mAb substantially reversed high dose SEB-dependent down-regulation effected by CD8* but had no appreciable effects on high dose SEB-dependent killing of activated B cells. These observations strongly suggest that the small fraction of activated B cells that secrete Ig are selectively sensitive to CD95-based killing but resistant to CD95-independent killing. This finding may help explain why clinical autoimmunity associated with increased titers of autoantibodies is a predominant feature of defects in CD95 or CD95 ligand.




This article has been cited by other articles:


Home page
J. Immunol.Home page
Y. Yan, T. Devos, L. Yu, G. Xia, O. Rutgeerts, J. Goebels, C. Segers, Y. Lin, M. Vandeputte, and M. Waer
Pathogenesis of Autoimmunity After Xenogeneic Thymus Transplantation
J. Immunol., June 15, 2003; 170(12): 5936 - 5946.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
S.-U. Lee, W. Ferens, W. C. Davis, M. J. Hamilton, Y.-H. Park, L. K. Fox, J. Naessens, and G. A. Bohach
Identity of Activation Molecule 3 on Superantigen-Stimulated Bovine Cells Is CD26
Infect. Immun., November 1, 2001; 69(11): 7190 - 7193.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
O. T. M. Chan, V. Paliwal, J. M. McNiff, S.-H. Park, A. Bendelac, and M. J. Shlomchik
Deficiency in {beta}2-Microglobulin, But Not CD1, Accelerates Spontaneous Lupus Skin Disease While Inhibiting Nephritis in MRL-Faslpr Mice: An Example of Disease Regulation at the Organ Level
J. Immunol., September 1, 2001; 167(5): 2985 - 2990.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
E. S. Bergmann-Leitner and S. I. Abrams
Differential Role of Fas/Fas Ligand Interactions in Cytolysis of Primary and Metastatic Colon Carcinoma Cell Lines by Human Antigen-Specific CD8+ CTL
J. Immunol., May 1, 2000; 164(9): 4941 - 4954.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1998 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1998 by The American Association of Immunologists, Inc. All rights reserved.